



EUROPEAN COMMISSION
JOINT RESEARCH CENTRE

Directorate F – Health and Food
Disease Prevention

Annual Declaration of Interests¹ (DoI) form (v3)

European Commission Initiative on Breast Cancer (ECIBC)

Please answer each of the questions below.

If the answer to any of the questions is "Yes"², please complete the corresponding fields, describing the circumstances, as appropriate.

If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the current ECIBC activities.

If you do not disclose relevant activities of interest for the ECIBC, your role may be revised.

¹ According to European Commission's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 11 each member of an expert group has to complete a DoI form

[https://ec.europa.eu/transparency/documents-register/detail?ref=C\(2016\)3301&lang=en](https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en)

² Answering "Yes" to the questions on this form does not automatically limit your participation in the ECIBC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (i.e. any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

Name and Surname:	Mireille Broeders
--------------------------	--------------------------

Activities	Yes/No	Period (From - To)	Information	Details
1. Do you have current investments³ in a legal entity⁴ with an interest related to breast cancer which either: <ul style="list-style-type: none"> • has a value of more than 10.000 EUR, or • entitle you to a voting right of 5% or more? 	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please provide information about where the investment is placed (Name, Country, Public/Private).	[Please describe the entity and your role.]
2. Have you, within the last five years (January 2018 – December 2022), received remuneration from a legal entity with an interest related to breast cancer? A. Employment	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please specify: <ul style="list-style-type: none"> • Name, Place of the entity; • Type of the entity: public, private, etc.; • The received amounts for remunerated activities. 	[Please describe your role.]

³ **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (e.g., proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

⁴ **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities	Yes/No	Period (From - To)	Information	Details
B. Consultancy, including advisory activities	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please specify: <ul style="list-style-type: none"> • Name, Place of the entity; • Type of the entity: public, private, etc.; The received amounts for remunerated activities.	Please describe your role.

Activities	Yes/No	Period (From - To)	Information	Details
<p>3. Have you, within the past five years (January 2018 – December 2022), been involved in research related to breast cancer?</p> <p>A. Have you been an investigator in research studies on breast cancer?</p> <p>B. For the mentioned research studies, did you receive support⁵?</p>	<p>Yes <input checked="" type="checkbox"/></p> <p>No <input type="checkbox"/></p>	<p>01/2023-01/2028</p> <p>01/2023-01/2027</p> <p>01/2021 – 12/2024</p> <p>08/2020 – 11/2024</p> <p>06/2019 – 05/2023</p> <p>03/2016 – 12/2021</p> <p>03/2015 – 02/2019</p> <p>06/2013 – 12/2021</p>	<p>Digital Breast Tomosynthesis for the Dutch National Breast Cancer Screening Program</p> <p>Digital Breast Tomosynthesis for the Dutch National Breast Cancer Screening Program</p> <p>Breast CALcification Risk Evaluation Study (Breast-CARE Study).</p> <p>aiREAD – Accurate and Intelligent Reading for Earlier breast cancer Detection.</p> <p>Combining features from in-depth mammography analysis and pathology to optimize referral of possible invasive breast cancers at screening (IMAGINE).</p> <p>Early detection of breast cancer – from one-size-fits-all to Personalised RISK-based MAMmography screening (PRISMA).</p> <p>Acceptability of personalized risk-based breast cancer screening and prevention approaches among women in Europe.</p> <p>Breast cancer screening – from a one-size-fits-all to a personalised risk-based approach.</p>	<p>Project leader and PI. No results published yet.</p> <p>Project leader and PI. No results published yet.</p> <p>Co-PI. No results published yet.</p> <p>Co-PI. Abstracts accepted for conferences.</p> <p>Project leader and PI. No results published yet.</p> <p>Project leader and PI. Abstracts accepted for conferences.</p> <p>Project leader and PI. Results published.</p> <p>Project leader and PI. Abstracts accepted for conferences.</p>
<p>⁵ Support refers to research support (i.e. grants, collaborations, sponsorships) as well as non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).</p>				
<p>European Commission - Joint Research Centre · via E. Fermi, 2749 · I-21027 Ispra (VA), Italy · TP 127 JRC-CANCER-POLICY-SUPPORT@ec.europa.eu</p>				

Activities	Yes/No	Period (From - To)	Information	Details
	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	01/2023-01/2028	Grant, KWF Dutch Cancer Society, Amsterdam, private, EUR 734.538. In-kind co-funding from vendors 1.321.600 EUR.	Digital Breast Tomosynthesis for the Dutch National Breast Cancer Screening Program
		01/2023-01/2027	Grant, ZonMw Vroege Opsporing, Den Haag, public, EUR 599.110. In-kind co-funding from vendors 248.000 EUR.	Digital Breast Tomosynthesis for the Dutch National Breast Cancer Screening Program
		01/2021 – 12/2024	Grant, ZonMw Vroege Opsporing, Den Haag, public, EUR 400.000.	Breast CALcification Risk Evaluation Study (Breast-CARE Study).
		08/2020 – 11/2024	Grant, KWF Dutch Cancer Society, NWO Domain AES, and Top Sector LSH, Technology for Oncology II, public/private, EUR 1.183.000.	aiREAD – Accurate and Intelligent Reading for Earlier breast cancer Detection.
		06/2019 – 05/2023	Grant, KWF Dutch Cancer Society, Amsterdam, private, EUR 730.260.	Combining features from in-depth mammography analysis and pathology (IMAGINE).
		03/2016 – 12/2021	Grant, KWF Dutch Cancer Society, Amsterdam, private, EUR 569.900.	Early detection of breast cancer – PRISMA
		03/2015 – 02/2019	Grant, Radboud Institute for Health Sciences, Radboudumc, Nijmegen, public, EUR 240.000.	Acceptability of personalized risk-based breast cancer screening and prevention approaches among women in Europe.
		06/2013 – 02/2021	Grant, ZonMw, programma TOP Fructus, Den Haag, public, EUR 674.659.	Breast cancer screening – from a one-size-fits-all to a personalised risk-based approach.

4. Do you have a membership in national or international organisations⁶, including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies with an interest in breast cancer?	Yes <input checked="" type="checkbox"/>	12/2021 – current	Member of Committee on Population Screening, Dutch Health Council, public	The task of the Committee on Population Screening is twofold: to identify developments in population screening and assess permit applications in connection with the Population Screening Act.
	No <input type="checkbox"/>	01/2020 – current	Chair of Steering Committee, International Cancer Screening Network (ICSN), public	ICSN promotes evidence-based cancer screening implementation and research with cooperation from multilateral organizations around the globe.
		11/2007 – current	Member of working group ‘Communication and expertise enhancement’ for breast cancer screening, Centre for Population Screening, National Institute for Health and the Environment (RIVM), public	The working group provides advice to the Centre for Population Screening, RIVM, which manages and coordinates the national population screening programmes for cervical cancer, breast cancer and colorectal cancer.
		06/1998 – current	Member of National Evaluation Team for Breast Cancer Screening (NETB), public	The NETB has been entrusted with the ongoing evaluation of the breast cancer screening programme.
		08/2016 – 12/2020	External Advisory Board H2020 consortium PAMMOTH, Twente, NL, public	Scientific advisory body.
		09/2018 – current	EUREF Scientific Board, Chair Epidemiology Group, public	Scientific advisory body.
		12/2015 – 12/2021	External Advisory Board H2020 consortium BRIDGES, Leiden, NL, public	Scientific advisory body.

⁶ **Organisation** refers to a governmental, international or non-profit organisation.

Activities	Yes/No	Period (From - To)	Information	Details
6. Do you have intellectual property rights (IPR)⁷ related to breast cancer?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please specify the title of the IPR.	Please describe the IPR.
7. Do any of your immediate family members⁸ have direct interests related to breast cancer that could undermine your independence?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the interest.	Please describe the interest.

⁷ **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

⁸ **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

Notes:

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published⁹ before you send the DoI form to the Joint Research Centre (JRC), European Commission.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending a message as soon as possible to: JRC-CANCER-POLICY-SUPPORT@ec.europa.eu.

- I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.
- I agree my DoI form to be publicly available on the JRC Healthcare Quality website, during the European Commission Initiative on Breast Cancer subgroup membership¹⁰.
- I am informed that my personal data are stored, processed and published by the European Commission in accordance with Regulation (EU) 2018/1725¹¹.

Name and Surname: Mireille Broeders

Date: 7 April 2023

Signature:

Place: Nijmegen, NL



⁹ Personal data processing including the Declaration of Interests

<https://ec.europa.eu/dpo-register/detail/DPR-EC-00656>

¹⁰ Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.

¹¹ Protection of individuals with regard to the processing of personal data

<https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725>